Real-world outcomes for high-risk myelodysplastic syndrome remain suboptimal

ByAshley Killen

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — Patients with higher-risk myelodysplastic syndrome continue to experience suboptimal outcomes, according to study results presented at ASH Annual Meeting and Exposition.

Duration of treatment with hypomethylating agents also appears short, results showed.

Healio spoke with researcher Roger M. Lyons, MD, medical director of hematology and laboratory services for Texas Oncology and The US Oncology Network, about the findings from this real-world analysis and their potential implications.

Lyons also addressed the need for novel treatment options to be evaluated in the community oncology setting.

Published by:

Sources/Disclosures

Collapse

Source:

Lyons RM, et al. Abstract 3085. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Disclosures: Lyons reports a consulting role with Incyte Corporation and honoraria from Celgene. Please see the abstract for all other researchers’ relevant financial disclosures.

ASH Annual Meeting and Exposition

Read more

Real-world outcomes for high-risk myelodysplastic syndrome remain suboptimal

Related Content